Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Report
RA01190
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global human immunodeficiency virus (hiv)-1 therapeutics market is estimated to surpass $16,140.8 million by 2027, exhibiting a CAGR of 1.5% from 2020 to 2027.
OFFERINGS OF THE REPORT:
The report offers comprehensive analysis of the global human immunodeficiency virus (hiv)-1 therapeutics market by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market.
The report also sheds light on present scenario and upcoming trends and developments that are contributing in the growth of the market. In addition, key market boomers and opportunities driving the market growth are provided in the report. Besides, restraints and challenges that hold power to obstruct the market growth are also profiled in the report. The report also offers Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.
Based on the key forces molding the market, the report offers future perspective and growth outlook of the global market. The report offers market size and forecast by keenly evaluating every segment of the global human immunodeficiency virus (hiv)-1 therapeutics market. Regional market breakdown of these segments is also offered in the report. The report divides the global human immunodeficiency virus (hiv)-1 therapeutics market into four main regions including Europe, North America, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-divided to profile detailed panorama of the human immunodeficiency virus (hiv)-1 therapeutics market across major countries in specific regions. Moreover, the report reveals some of the recent developments, trends, and forthcoming opportunities in every region.
HIGHLIGHTS OF THE MARKET
- The report offers market size and forecast for the period from 2019 to 2027
- This report highlights trends, innovations, and new developments along with a detailed quantitative analysis of the human immunodeficiency virus (hiv)-1 therapeutics market during the period of forecast
- The prevailing and upcoming opportunities along with the tactical assessment of the global human immunodeficiency virus (hiv)-1 therapeutics market growth is provided
- The market size and estimations are based on a comprehensive analysis of market drivers and restraints and key innovations in the human immunodeficiency virus (hiv)-1 therapeutics market
- Information on leading market players, Porter’s Five Analysis, and top winning business strategies is offered
- The development plans and initiatives undertaken by the top market players are highlighted to understand the competitive landscape of the market
KEY MARKET SEGMENTS
The report segments the global market into drug class
- Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists
Region:
The global human immunodeficiency virus (hiv)-1 therapeutics market is divided into North America, Europe, Asia Pacific, and LAMEA.
The above-mentioned regions are further dived in countries as follows:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
LEADING PLAYERS OF THE MARKET
The most influential companies are mentioned in the report which include Boehringer Ingelheim GmbH, Cipla, Inc., AbbVie, Inc., Genentech, Inc.
The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the human immunodeficiency virus (hiv)-1 therapeutics market.
1. AbbVie, Inc.
2. Merck & Co., Inc.
3. Bristol-Myers Squibb Company
4. Boehringer Ingelheim GmbH
5. Genentech, Inc.
6. Cipla, Inc.
RESEARCH METHODOLOGY
The report is formulated by in-house market analysts by deeply scrutinizing the market scenario. The market predictions stated in the report have been derived using proven research methodologies and analytical tools & models. Use of such advanced and effective tools, helps market analysts in scrutinizing, filtering, and offering highly accurate data and predictions. The report delivers an extensive research and analysis backed with a variety of factual data, which mainly include interviews with industry players, trustworthy and renowned sources of statistics, and regional intelligence. The insights provided in the report can help investors in understanding investment suitability and market players to grab opportunities for investments, partnerships, and developments in the global market.
The research report is formed by collating different statistics and information concerning the human immunodeficiency virus (hiv)-1 therapeutics market. For instance, around 18 hours of interviews and deliberations have been performed with a group of stakeholders and investors, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. About 5,900 product type literatures, market publications, company annual reports, and other such relevant documents of key market players have been studied, for better understanding of market penetration. Furthermore, trustworthy industry newsletters, medical journals, trade associations’ publications, and government websites have also been evaluated for extracting vital industry insights.
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Model
5.1. Overview
5.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Entry and Fusion Inhibitors
5.4.1 Definition, key trends, growth factors, and opportunities
5.4.2 Market size analysis, by region, 2020-2027
5.4.3 Market share analysis, by country, 2020-2027
5.5 Protease Inhibitors (PIs)
5.5.1 Definition, key trends, growth factors, and opportunities
5.5.2 Market size analysis, by region, 2020-2027
5.5.3 Market share analysis, by country, 2020-2027
5.6 Integrase Inhibitors
5.6.1 Definition, key trends, growth factors, and opportunities
5.6.2 Market size analysis, by region, 2020-2027
5.6.3 Market share analysis, by country, 2020-2027
5.7 Coreceptor Antagonists
5.7.1 Definition, key trends, growth factors, and opportunities
5.7.2 Market size analysis, by region, 2020-2027
5.7.3 Market share analysis, by country, 2020-2027
5.8 Research Dive Exclusive Insights
5.8.1 Market attractiveness
5.8.2 Competition heatmap
6. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Region
6.1 North America
6.1.1 U.S
6.1.1.1 Market size analysis, By Model, 2020-2027
6.1.2 Canada
6.1.2.1 Market size analysis, By Model, 2020-2027
6.1.3 Mexico
6.1.3.1 Market size analysis, By Model, 2020-2027
6.1.4 Research Dive Exclusive Insights
6.1.4.1 Market attractiveness
6.1.4.2 Competition heatmap
6.2 Europe
6.2.1 Germany
6.2.1.1 Market size analysis, By Model, 2020-2027
6.2.2 UK
6.2.2.1 Market size analysis, By Model, 2020-2027
6.2.3 France
6.2.3.1 Market size analysis, By Model, 2020-2027
6.2.4 Spain
6.2.4.1 Market size analysis, By Model, 2020-2027
6.2.5 Italy
6.2.5.1 Market size analysis, By Model, 2020-2027
6.2.6 Rest of Europe
6.2.6.1 Market size analysis, By Model, 2020-2027
6.2.7 Research Dive Exclusive Insights
6.2.7.1 Market attractiveness
6.2.7.2 Competition heatmap
6.3 Asia-Pacific
6.3.1 China
6.3.1.1 Market size analysis, By Model, 2020-2027
6.3.2 Japan
6.3.2.1 Market size analysis, By Model, 2020-2027
6.3.3 India
6.3.3.1 Market size analysis, By Model, 2020-2027
6.3.4 Australia
6.3.4.1 Market size analysis, By Model, 2020-2027
6.3.5 South Korea
6.3.5.1 Market size analysis, By Model, 2020-2027
6.3.6 Rest of Asia-Pacific
6.3.6.1 Market size analysis, By Model, 2020-2027
6.3.7 Research Dive Exclusive Insights
6.3.7.1 Market attractiveness
6.3.7.2 Competition heatmap
6.4 LAMEA
6.4.1 Brazil
6.4.1.1 Market size analysis, By Model, 2020-2027
6.4.2 Saudi Arabia
6.4.2.1 Market size analysis, By Model, 2020-2027
6.4.3 UAE
6.4.3.1 Market size analysis, By Model, 2020-2027
6.4.4 South Africa
6.4.4.1 Market size analysis, By Model, 2020-2027
6.4.5 Rest of LAMEA
6.4.5.1 Market size analysis, By Model, 2020-2027
6.4.6 Research Dive Exclusive Insights
6.4.6.1 Market attractiveness
6.4.6.2 Competition heatmap
7. Competitive Landscape
7.1 Top winning strategies, 2020-2027
7.1.1 By strategy
7.1.2 By year
7.2 Strategic overview
7.3 Market share analysis, 2020-2027
8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Overview
8.1.2 Business segments
8.1.3 Product portfolio
8.1.4 Financial performance
8.1.5 Recent developments
8.1.6 SWOT analysis
8.2 Merck & Co., Inc.
8.2.1 Overview
8.2.2 Business segments
8.2.3 Product portfolio
8.2.4 Financial performance
8.2.5 Recent developments
8.2.6 SWOT analysis
8.3 Bristol-Myers Squibb Company
8.3.1 Overview
8.3.2 Business segments
8.3.3 Product portfolio
8.3.4 Financial performance
8.3.5 Recent developments
8.3.6 SWOT analysis
8.4 Boehringer Ingelheim GmbH
8.4.1 Overview
8.4.2 Business segments
8.4.3 Product portfolio
8.4.4 Financial performance
8.4.5 Recent developments
8.4.6 SWOT analysis
8.5 Genentech, Inc.
8.5.1 Overview
8.5.2 Business segments
8.5.3 Product portfolio
8.5.4 Financial performance
8.5.5 Recent developments
8.5.6 SWOT analysis
8.6 Cipla, Inc.
8.6.1 Overview
8.6.2 Business segments
8.6.3 Product portfolio
8.6.4 Financial performance
8.6.5 Recent developments
8.6.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
